{
  "id": 8781635,
  "title": "A self-limiting, TREM2-dependent anabolic program confers microglial resilience in Alzheimer's disease",
  "url": "https://urgent.news/2026/09/20/a-self-limiting-trem2-dependent-anabolic-program-confers-microglial",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-20T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.16.752098v1?rss=1"
  },
  "original_language": "en",
  "account": "Microglia play a crucial role in the progression of Alzheimer's disease (AD), with TREM2 being a major genetic risk factor. This gene enables the development of the disease-associated microglia (DAM) state, which is necessary for engaging amyloid plaques. However, the mechanism by which TREM2 sustains this protection and why it diminishes as the disease advances is still not well understood. By employing proteomics, single-cell transcriptomics, and in vivo metabolic labeling, researchers have discovered that plaque-associated microglia initiate a TREM2-dependent anabolic program. This program links new protein synthesis with mitochondrial biogenesis. Crucially, this program, not the DAM signature, distinguishes phagocytically competent microglia. The loss of this anabolic program is linked to proteostatic overload and mitochondrial dysfunction. Interestingly, this self-limiting anabolic program reaches its peak at low amyloid burden and declines as the burden increases. This decline mirrors the pattern observed in humans, where anabolic capacity correlates with TREM2 levels but decreases at advanced stages of the disease, even as the DAM signature continues to rise. Therefore, the researchers conclude that anabolic capacity, rather than activation state, is a key indicator of microglial resilience in AD. Consequently, continuous stimulation of phagocytosis through anti-amyloid antibodies may lead to biosynthetic exhaustion and a self-limiting efficacy in combating the disease.",
  "summary": "Microglia are key drivers of Alzheimer's disease (AD), and TREM2, one of the strongest genetic risk factors, enables the disease-associated microglia (DAM) state required for plaque engagement. How TREM2 sustains this protection, and why it falters as disease advances, remain unclear. Using proteomics, single-cell transcriptomics, and in vivo metabolic labeling, we show that plaque-associated…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}